GeoVax Labs, Inc. has highlighted the potential of its multi-antigen COVID-19 vaccine candidates, GEO-CM04S1 and GEO-CM02, to provide durable and cross-reactive immunity against various SARS-CoV-2 variants, including the Omicron XBB.1.5 subvariant. The findings, presented at the Keystone Symposia, underscore the vaccines' ability to induce protective immune responses not solely reliant on neutralizing antibodies, but also on T-cell mediated immunity.
The studies demonstrated that GEO-CM02, a vaccine expressing spike, membrane, and envelope proteins, offered complete protection against the original Wuhan strain and Omicron BA.1 variant in preclinical models. Similarly, GEO-CM04S1, co-expressing spike and nucleocapsid proteins, provided full protection against clinical disease and lung injury in models challenged with the original B.1 strain or Omicron XBB.1.5 subvariant, even in the absence of detectable neutralizing antibodies against XBB.1.5.
These results suggest that GeoVax's multi-antigen vaccine strategy could significantly contribute to pandemic preparedness by reducing the need for frequent vaccine updates and booster doses. The ability to induce broad immune responses is particularly crucial for protecting vulnerable populations, such as immunocompromised individuals, against evolving variants.
GeoVax's MVA vaccine platform, with its lead candidate GEO-CM04S1 currently in multiple Phase 2 clinical trials, represents a promising approach to addressing the challenges posed by SARS-CoV-2 variants. The platform's focus on inducing both antibody and T-cell responses could offer a more robust and durable solution to COVID-19 vaccination, marking an important step forward in the global fight against the pandemic.
